Hepatocellular Carcinoma Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032)| Key Companies – Sanofi, Kyamb

DelveInsight Business Research LLP

DelveInsight’s “Hepatocellular Carcinoma Market Insights, Epidemiology, and Market Forecast — 2032” report delivers an in-depth understanding of the Hepatocellular Carcinoma, historical and forecasted epidemiology as well as the Hepatocellular Carcinoma (HCC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Hepatocellular Carcinoma Overview

 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Tests and procedures used to diagnose hepatocellular carcinoma include:Blood tests to measure liver function imaging tests, such as CT and MRILiver biopsy, in some cases, to remove a sample of liver tissue for laboratory testing.

Hepatocellular Carcinoma Epidemiology Insights

• According to the Global Cancer Observatory, in the 7MM the ASR incident rate of liver cancer is 7.4/100,000 which is estimated to be around 135,533 new cases in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 100,793 number of deaths in 2020. Apart from the other data, nearly XX% of liver cancer is HCC.

• According to the Global Cancer Observatory, in Japan, the ASR incident rate of liver cancer is 10.4/100,000 which is estimated to be around 45,663 new cases diagnosed in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 28,155  number of deaths in 2020.

• As per the National Cancer Institute, the combination treatment worked better than sorafenib. More people who were treated with the combination than with sorafenib were still alive after 1 year: 67% in the combination group and 55% in the sorafenib group. 

• According to the Global Cancer Observatory in the United Kingdom the ASR incident rate of liver cancer is 5.3/100,000 which is estimated to be around 8,156 new cases diagnosed in 2020 and the ASR mortality rate of liver cancer is 4.1/100,000 which is estimated to be around 7,061 number of deaths in 2020

Click here to learn more about the Hepatocellular Carcinoma Market Landscape

The Report Covers the Hepatocellular Carcinoma Epidemiology Segmented by:

• Hepatocellular Carcinoma incident cases 

• Total Hepatocellular Carcinoma stage-wise cases 

• Total Hepatocellular Carcinoma treated cases 

Hepatocellular Carcinoma Market Outlook 

There are currently six FDA-approved immunotherapy options for Hepatocellular Carcinoma. Several other immunotherapies are currently being tested in Hepatocellular Carcinoma clinical trials, including oncolytic viruses and adoptive cell therapy. Hence, the therapy market also includes AVASTIN (bevacizumab) a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for subsets of patients with advanced Hepatocellular Carcinoma.

Among patients who have successful surgeries, the rate of recurrence can be 50% or higher. In the current study, the researchers found that the five patients who underwent surgery and had their tumors shrink significantly have remained disease-free for more than 230 days so far. Around 60% of patients who did not have a significant tumor response developed disease progression between 56 and 155 days after the end of treatment.

According to DelveInsight, the Hepatocellular Carcinoma market in 7MM is expected to witness a major change in the study period 2019-2032.

Key Companies Working in the Hepatocellular Carcinoma Market

• H3 Biomedicine,

• Geoscience Pharma, 

• Kymab, 

• Sanofi, 

• Exelixis

And many others

Hepatocellular Carcinoma Therapies Covered and Analyzed in the Report

• Ensifentrine

• ELX-02 

• Lonodelestat

And many others 

Learn more about the Key Companies and Emerging Therapies in the Hepatocellular Carcinoma Market

Table of Contents 

1. Key Insights 

2. Hepatocellular Carcinoma  Introduction 

3. Executive Summary of Hepatocellular Carcinoma           

4. Disease Background and Overview

5. Epidemiology and patient population

6. Hepatocellular Carcinoma  Emerging Therapies

7. Hepatocellular Carcinoma  Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Hepatocellular Carcinoma Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services